CN1137682C - 一种治疗剂 - Google Patents
一种治疗剂 Download PDFInfo
- Publication number
- CN1137682C CN1137682C CNB998079278A CN99807927A CN1137682C CN 1137682 C CN1137682 C CN 1137682C CN B998079278 A CNB998079278 A CN B998079278A CN 99807927 A CN99807927 A CN 99807927A CN 1137682 C CN1137682 C CN 1137682C
- Authority
- CN
- China
- Prior art keywords
- furancarboxylic acid
- activity
- chemical compound
- aldose reductase
- dihydroxy tetrahydrochysene
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/04—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D307/18—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D307/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Engineering & Computer Science (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
酶反应体系中的浓度(μg/ml) | 活性抑制率(%) |
0.5 | 8.1 |
5 | 34.8 |
50 | 81.6 |
500 | 96.3 |
Claims (4)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP195149/1998 | 1998-06-26 | ||
JP19514998 | 1998-06-26 | ||
JP195149/98 | 1998-06-26 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1307474A CN1307474A (zh) | 2001-08-08 |
CN1137682C true CN1137682C (zh) | 2004-02-11 |
Family
ID=16336258
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB998079278A Expired - Fee Related CN1137682C (zh) | 1998-06-26 | 1999-06-25 | 一种治疗剂 |
Country Status (6)
Country | Link |
---|---|
US (1) | US6492338B1 (zh) |
EP (1) | EP1099440A4 (zh) |
KR (1) | KR20010052814A (zh) |
CN (1) | CN1137682C (zh) |
CA (1) | CA2334312A1 (zh) |
WO (1) | WO2000000190A1 (zh) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6989024B2 (en) | 2002-02-28 | 2006-01-24 | Counter Clockwise, Inc. | Guidewire loaded stent for delivery through a catheter |
FR2870742B1 (fr) * | 2004-05-28 | 2008-03-14 | Expanscience Laboratoires Sa | Utilisation d'alkyle furannes pour la preparation d'un medicament destine au traitement du diabete, de l'obesite et pour le traitement cosmetique de la cellulite et de la surcharge ponderale |
US9144508B2 (en) | 2007-07-19 | 2015-09-29 | Back Bay Medical Inc. | Radially expandable stent |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8401149D0 (en) * | 1984-01-17 | 1984-02-22 | Fujisawa Pharmaceutical Co | Furanone derivatives |
JPH0813739B2 (ja) * | 1986-12-03 | 1996-02-14 | 武田薬品工業株式会社 | 白内障治療剤 |
US4826872A (en) | 1986-12-03 | 1989-05-02 | Takeda Chemical Industries, Ltd. | Pharmaceutical composition for treatment of cataract |
JPH08337525A (ja) * | 1995-04-13 | 1996-12-24 | Kikkoman Corp | 白内障の予防または治療薬剤 |
US5698585A (en) | 1995-04-13 | 1997-12-16 | Kikkoman Corporation | Pharmaceutical preparation for prevention and/or treatment for cataract |
KR100514071B1 (ko) | 1997-01-27 | 2005-09-09 | 다카라 바이오 가부시키가이샤 | 테트라하이드로퓨란 유도체 |
-
1999
- 1999-06-25 KR KR1020007014136A patent/KR20010052814A/ko not_active Application Discontinuation
- 1999-06-25 US US09/720,308 patent/US6492338B1/en not_active Expired - Fee Related
- 1999-06-25 EP EP99926822A patent/EP1099440A4/en not_active Withdrawn
- 1999-06-25 WO PCT/JP1999/003404 patent/WO2000000190A1/ja not_active Application Discontinuation
- 1999-06-25 CA CA002334312A patent/CA2334312A1/en not_active Abandoned
- 1999-06-25 CN CNB998079278A patent/CN1137682C/zh not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
CN1307474A (zh) | 2001-08-08 |
CA2334312A1 (en) | 2000-01-06 |
KR20010052814A (ko) | 2001-06-25 |
WO2000000190A1 (fr) | 2000-01-06 |
EP1099440A1 (en) | 2001-05-16 |
US6492338B1 (en) | 2002-12-10 |
EP1099440A4 (en) | 2005-01-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5536229B2 (ja) | Hcv併用療法 | |
EP2298295B1 (en) | Tumor necrosis factor inhibitors | |
MX2011001426A (es) | Metodos para tratar la talasemia. | |
JPH02111724A (ja) | アデニンヌクレオチドを有効成分とする血液および血漿中のアデノシン5’‐トリホスフェートレベルを増加させる薬剤 | |
HU184219B (en) | Process for producing pharmaceutical compositions of aggragati on-inhiaiting activity | |
JPH04243822A (ja) | カルシウム拮抗剤 | |
CN1568999A (zh) | 稳定的医药用河豚毒素冷冻干燥制剂 | |
CN1137682C (zh) | 一种治疗剂 | |
KR920000892B1 (ko) | 각화증 치료제 | |
CN114349745B (zh) | 一种用于治疗心肌缺血的药物及其制备方法 | |
JP2687398B2 (ja) | アルドースリダクターゼ阻害剤 | |
JPH0383929A (ja) | 血糖降下剤 | |
JPH0368516A (ja) | Na↑+,K↑+‐ATPase阻害剤 | |
JPH0368517A (ja) | アルドースリダクターゼ阻害剤 | |
JP6862447B2 (ja) | ダニリキシンの静脈内注射用製剤 | |
EP2899186A1 (en) | New hydroxysafflor yellow pharmaceutical salts | |
CN1431901A (zh) | 用于治疗精神病和眼科疾病的s-甲基-二氢一齐拉昔酮 | |
JPH03271226A (ja) | 腎炎治療剤 | |
JP7257091B2 (ja) | 認知症の治療及び予防薬 | |
US4791105A (en) | Therapeutic and preventive agent containing dolichol | |
JPH04159280A (ja) | ヒドロキシスチルベン系化合物を有効成分とする5―リポキシゲナーゼ阻害剤 | |
JPH01224367A (ja) | ポリアセチレン系化合物類、およびポリアセチレン系化合物類を有効成分とする5−リポキシゲナーゼ阻害剤 | |
WO1995002407A1 (fr) | Neuroprotecteur et nouvel ester orotique | |
JP4366533B2 (ja) | 睡眠障害の治療剤 | |
JPH07233060A (ja) | 血管拡張剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: TAKARA BIO INC. Free format text: FORMER OWNER: BAO HOLDINGS LIMITED Effective date: 20040827 |
|
C41 | Transfer of patent application or patent right or utility model | ||
C56 | Change in the name or address of the patentee |
Owner name: BAO HOLDINGS LIMITED Free format text: FORMER NAME OR ADDRESS: TAKARA SHUZO CO., LTD. |
|
CP03 | Change of name, title or address |
Address after: Kyoto City Patentee after: Takara Holdings Inc. Address before: Kyoto City, Kyoto, Japan Patentee before: TAKARA SHUZO Co.,Ltd. |
|
TR01 | Transfer of patent right |
Effective date of registration: 20040827 Address after: The Japanese city of Tianjin Patentee after: Takara Bio Inc. Address before: Kyoto City Patentee before: Takara Holdings Inc. |
|
C19 | Lapse of patent right due to non-payment of the annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |